Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
about
Contemporary Treatment of Metastatic Renal Cell CarcinomaA Perspective of Immunotherapy for Prostate CancerTumor-intrinsic oncogene pathways mediating immune avoidanceBiomarkers for glioma immunotherapy: the next generationNew modalities of cancer treatment for NSCLC: focus on immunotherapyImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialMaking Better Chimeric Antigen Receptors for Adoptive T-cell TherapyExpression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Rationale for combining immunotherapy with chemotherapy.Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.Targeting the immune system to treat lung cancer: rationale and clinical experience.Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung CancerTargeted agents and combinations in ovarian cancer: where are we now?Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.Drug-induced hepatotoxicity in cancer patients - implication for treatment.Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysisCancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.A new paradigm for tumor immune escape: β-catenin-driven immune exclusionImpact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis.How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression.Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
P2860
Q26740594-F05AD005-A995-4545-B560-212AC40E0FB4Q26741277-CEF1BCC1-41D3-4618-A2BF-48ABEFD65801Q26747707-CEC828AC-C668-400A-8FA4-16EEB42511D9Q26825496-CCC74C0E-C23E-4F1D-93C3-075620CE2AA9Q26829161-EAE1D331-DEA0-4356-90EA-B509C72AE2ACQ26996829-84D6E1AE-0C35-40B1-A0A3-7CB29FCE975CQ30275174-38A22209-C7E5-4B1A-AF2B-C39777A75444Q33924667-DB83247F-9639-4B73-B2BE-045DAF06909DQ36726204-4BDCC75D-568A-415A-8109-206E1D65367CQ36830759-6FB9B5A4-CDC7-4530-9DBE-2F36FA78CBEEQ36962460-6203FD53-FE5B-421C-B4BF-A60F9427BE7EQ37079131-29710C4A-71B1-4217-AB42-5792B4903FF7Q37191649-73BDD84E-7715-462B-97CC-C21DC967745FQ38123176-6C679C5A-D3F6-422B-AEB2-DA6A6BB59F3CQ38389326-B135ACE7-FA5A-4443-BEDD-2E4DA6BD0645Q38391922-2ECD2BF6-3AAC-45F6-B35D-12DBF55250B3Q38397629-F7BAEA38-F1DB-4105-B23A-3CA0B3A53B52Q38541767-7C0C90D5-BA94-485A-A8CA-D57E1C50E29BQ38735467-D4766306-2537-48D2-B289-33D63C2B07A5Q38760610-9762EA09-65B4-4E10-A7C0-259AA305F41EQ38844500-7554E9F2-9C82-4156-99DF-497239DAFB85Q38845891-09DEFB2A-C435-495D-9ED1-89DEF15CB903Q38868038-2D2C50B1-3491-4C62-AC0F-21DD33F3BBEEQ38890681-0752A63A-698C-4F1D-A36B-8E3B636FB1DBQ38950573-89F8683F-52E6-41B1-A7AC-B0DA32DD4DDDQ38987399-A5AA6020-166C-419F-9A0D-3B1788456795Q39008859-2A1E136A-4306-45DD-B1DD-E495B5877696Q39096266-64E299A0-35F8-4CAC-8438-F97641207400Q41316099-F28FB572-51FA-4E0F-88C8-BD0C37D6B4D9Q41445876-C61AC72B-B1EB-4049-89B1-4CE526FB7B24Q41545176-944F43A1-48B9-4296-9896-6222ED5869E7Q41719867-6831CE9E-2E51-4F0D-93F4-9E33999A8E9DQ41826015-D896C85D-6592-442E-A696-6C50E11F860CQ41836927-6AB40F3D-C414-4281-98C9-2E2E235804CDQ42281477-8457909E-BFD5-44E5-B015-56D40BE706EDQ47120953-B2BE22F5-77C0-4DC1-9CAA-CA05CF68F2AAQ47145968-FCA775F8-461C-413E-B876-39AB77B4C460Q48539402-22E716D6-A365-42D1-A250-E551A150BB9AQ48785791-B70AB60F-F1DE-463A-9CD1-7FA6B9FDB568Q49494144-F28147DB-0434-480F-B37D-53B7014AD337
P2860
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
@en
type
label
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
@en
prefLabel
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
@en
P2860
P1476
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
@en
P2093
Omid Hamid
Richard D Carvajal
P2860
P304
P356
10.1517/14712598.2013.770836
P407
P577
2013-02-19T00:00:00Z